Ventyx Biosciences, Inc. Common Stock
VTYXVentyx Biosciences, Inc. is a biotechnology company focused on developing and commercializing therapies for immune-mediated diseases. The company is dedicated to discovering innovative treatments by targeting underlying biological mechanisms, with an emphasis on inflammatory and autoimmune conditions. Founded with a commitment to advancing patient care, Ventyx aims to leverage cutting-edge science to address unmet medical needs.
Company News
Halper Sadeh LLC, an investor rights law firm, is investigating potential securities law violations and fiduciary duty breaches related to Ventyx Biosciences' $14.00 per share sale to Eli Lilly and Sun Country Airlines' acquisition by Allegiant Travel Company for 0.1557 shares plus $4.10 cash per share. The firm seeks increased consideration for ...
Law firm Brodsky & Smith announced investigations into four merger agreements, examining whether company boards breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders. The investigations involve Nathan's Famous (acquired by Smithfield Foods for $102/share), Lisata Therapeutics (acquired by Kuva Labs ...
Halper Sadeh LLC, an investor rights law firm, is investigating three companies for potential violations of federal securities laws and breaches of fiduciary duties related to their merger transactions: ON24's sale to Cvent for $8.10 per share, Ventyx Biosciences' sale to Eli Lilly for $14.00 per share, and Sun Country Airlines' sale to Allegiant...
Eli Lilly's stock experienced volatility in early 2026 following Novo Nordisk's launch of its oral Wegovy pill on January 5, which initially triggered a 3.6% decline in LLY shares. However, the stock rebounded strongly on January 7 after Lilly announced its $1.2 billion acquisition of Ventyx Biosciences, gaining 4.1%. The Ventyx deal is viewed po...
Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws and breaches of fiduciary duties related to their merger and acquisition transactions. The firm is seeking increased consideration for shareholders and additional disclosures regarding these deals.
